Feride YILMAZ

Dr. Feride YILMAZ

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HYHasan Çağrı Yıldırım
Hasan Çağrı Yıldırım
DGDeniz Can Guven
Deniz Can Guven
OAOktay halit Aktepe
Oktay halit Aktepe
HTHAKAN TABAN
HAKAN TABAN
FYFeride YILMAZ
Feride YILMAZ
SYSuayib Yalcin
Suayib Yalcin
Purpose: With the widespread use of immunotherapy agents, we encounter treatment responses such as hyperprogression disease (HPD) that we have not seen with previous standard chemotherapy and targeted therapies. It is known that survival in patients with HPD is shorter than in patients without HPD. Therefore, it is important to know the factors that will predict HPD. We aimed to identify HPD-related factors in patients treated with immunotherapy. Methods: A total of 121 adult metastatic cancer patients treated with immunotherapy for any cancer were included. Baseline demographics, the ECOG performance status, type of tumors and baseline blood count parameters were recorded. Possible predisposing factors were evaluated with univariate and multivariate analyses. Results: The median age was 62.28 (interquartile range (IQR) 54.02–67.63) years, and the median follow-up was 12.26 (IQR 5.6–24.36) months. Renal cell carcinoma (33%) and melanoma (33.8%) were the most common diagnoses. Twenty patients (16.5%) had HPD. A high LDH level (p: 0.001), hypoalbuminemia (p: 0.016) and an NLR > 5 (p: 0.007) were found to be associated with hyperprogression. Sex (female vs. male, p: 0.114), age (>65 vs. 5 (p: 0.007).

10 November 2021 in Seminars in Oncology
Verified
Journal Article
Closed access
FYFeride YILMAZ
Feride YILMAZ
SYSerkan Yasar
Serkan Yasar
MTMeltem Caglar Tuncali
Meltem Caglar Tuncali
SASerkan Akin
Serkan Akin

18 June 2025 in Medicina
Verified
Journal Article
Open access
PDF file
HTHAKAN TABAN
HAKAN TABAN
MEMustafa Erman
Mustafa Erman
DGDeniz Can Guven
Deniz Can Guven
BABurak Yasin Aktaş
Burak Yasin Aktaş
FYFeride YILMAZ
Feride YILMAZ
SASercan Aksoy
Sercan Aksoy
Background and Objectives: The prognostic nutritional index (PNI), a marker reflecting both nutritional and immune status, has been associated with prognosis in various malignancies. However, evidence in metastatic castration-resistant prostate cancer (mCRPC), particularly from non-Asian populations, remains limited. This study aimed to evaluate the prognostic value of baseline PNI and to develop a blood-based prognostic model in mCRPC patients treated with abiraterone acetate (AA), enzalutamide (ENZA), or cabazitaxel (CABA). Materials and Methods: This retrospective study included mCRPC patients treated with AA, ENZA, or CABA before or after docetaxel. PNI was calculated as: 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (/mm3). Patients were classified into low-PNI (≤40.8) and high-PNI (>40.8) groups using the median PNI value. Survival outcomes were analyzed using Kaplan–Meier and Cox regression methods. Results: A total of 299 patients were analyzed: 133 (44.5%) received AA, 106 (35.5%) ENZA, and 60 (20.0%) CABA. Patients with high PNI had significantly longer median overall survival (OS; 30.2 vs. 12.6 months, p < 0.001), radiologic progression-free survival (rPFS; 13.5 vs. 6.7 months, p < 0.001), and PSA progression-free survival (PSA-PFS; 10.2 vs. 5.1 months, p < 0.001). These associations remained significant across all treatment subgroups. In multivariate analysis, prostate surgery (HR: 0.6), high PNI (HR: 0.5), PSA response (HR: 0.5), and elevated ALP (HR: 1.6) were independent predictors of OS. A prognostic model incorporating PNI, alkaline phosphatase, and anemia stratified patients into four risk groups with distinct OS: 49.1, 30.8, 18.8, and 9.1 months, respectively. Conclusions: This is the largest study to date in a non-Asian mCRPC population showing that baseline PNI is a strong, independent prognostic factor for survival. The proposed blood-based tool may aid in clinical risk stratification, pending prospective validation.

1 October 2024 in BMC Cancer
Verified
Journal Article
Open access
PDF file
FYFeride YILMAZ
Feride YILMAZ
SYSerkan Yaşar
Serkan Yaşar
ÖTÖmer Denizhan Tatar
Ömer Denizhan Tatar
HYHasan Çağrı Yıldırım
Hasan Çağrı Yıldırım
DGDeniz Can Güven
Deniz Can Güven
MEMustafa Erman
Mustafa Erman
Despite initial dramatic responses, metastatic small cell lung cancer (SCLC) invariably recurs. Irinotecan is one of the active agents for patients with recurrent SCLC. In the second line, weekly or three-weekly irinotecan regimens have been adopted, however, the optimal dose and schedule is not defined. In our institution, we use a bi-weekly regimen of irinotecan. In this study, we aimed to investigate the safety and efficacy of the bi-weekly irinotecan in the second- or third-line treatment of SCLC patients. The study population consisted of advanced stage SCLC patients who were followed at Hacettepe University Cancer Institute between January 2007 and March 2021 and received salvage irinotecan 180 mg/m2 every two weeks, following progression after platinum-etoposide treatment. One hundred patients were included. At diagnosis, nineteen patients (19%) had limited stage and 81 patients (81%) had extensive stage SCLC. Objective response rates (ORR) were 44.6% and 46.2% for patients who received irinotecan treatment in second line, and in third line, respectively. Seventeen percent of all the patients had grade 3 and above adverse events during irinotecan treatment. In our study, 45.8% of patients were able to complete at least 6 cycles of irinotecan treatment and 69.8% were able to receive at least 3 cycles of irinotecan treatment without any dose interruption or reduction. Irinotecan 180 mg/m2 every two weeks appears to be safe and effective in the 2nd- and 3rd-line treatment of advanced stage SCLC. Bi-weekly administration allows G-CSF prophylaxis in between doses, leading to an uninterrupted administration.

25 September 2024 in Targeted Oncology
Verified
Journal Article
Closed access
PDF file
FYFeride YILMAZ
Feride YILMAZ
SYSerkan Yaşar
Serkan Yaşar
NMNil Molinas Mandel
Nil Molinas Mandel
TKTurgut Kaçan
Turgut Kaçan
MÖMelek Özdemir
Melek Özdemir
ŞYŞuayib Yalçın
Şuayib Yalçın

30 September 2024 in International Journal of Hematology and Oncology
Verified
Journal Article
Closed access
FYFeride YILMAZ
Feride YILMAZ
Colorectal cancers are the most common cancers of the gastrointestinal system. They rank third after prostate and lung cancer in men and after breast and lung cancer in women. In Turkiye, colon cancer is the third most common among all cancers. In such cancer, beyond the stage of the disease, there are many biological, molecular, genetic, and tissue-related factors that determine the prognosis. Among these, vascular invasion, the number of affected regional lymph nodes, and the levels of preoperative carcinoembryonic antigen (CEA) are prominent factors. In this study, we investigated the personal, clinical, tumoral, metastatic, and treatment characteristics of metastatic colon cancer (MCC) that may be associated with long survival. This study included the data of 103 patients diagnosed with MCC who were followed at the Medical Oncology Department of Karadeniz Technical University Faculty of Medicine between 2010 and 2016. In univariate analyses, primary surgery (p< 0.001), targeted therapy (p= 0.01), being less than 65 years old (p=0.02), having normal CEA levels (p= 0.03), and not having elevated platelet counts (p= 0.001) were significant factors associated with prolonged survival. Multivariate analysis indicated that survival was longer in patients who underwent primary surgery (p= 0.001, 95% CI: 0.07–0.52) and had normal or low platelet levels at the time of diagnosis (p= 0.001, 95% CI: 1.77–9.16), regardless of other factors. In patients diagnosed with MCC, those who had primary tumor surgery and had normal or low platelet levels at the time of diagnosis had a better prognosis regardless of other factors. Therefore, prognostic factors are important in MCC, and more comprehensive studies are needed on this subject. Keywords: Metastatic colorectal cancer, Survival, Prognostic factors